Back to Search
Start Over
Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce
- Source :
- Molecular Therapy. 25(2):512-522
- Publication Year :
- 2017
- Publisher :
- Elsevier BV, 2017.
-
Abstract
- Anti-drug antibodies in hemophilia patients substantially complicate treatment. Their elimination through immune tolerance induction (ITI) protocols poses enormous costs, and ITI is often ineffective for factor IX (FIX) inhibitors. Moreover, there is no prophylactic ITI protocol to prevent anti-drug antibody (ADA) formation. Using general immune suppression is problematic. To address this urgent unmet medical need, we delivered antigen bioencapsulated in plant cells to hemophilia B dogs. Commercial-scale production of CTB-FIX fusion expressed in lettuce chloroplasts was done in a hydroponic facility. CTB-FIX (∼1 mg/g) in lyophilized cells was stable with proper folding, disulfide bonds, and pentamer assembly after 30-month storage at ambient temperature. Robust suppression of immunoglobulin G (IgG)/inhibitor and IgE formation against intravenous FIX was observed in three of four hemophilia B dogs fed with lyophilized lettuce cells expressing CTB-FIX. No side effects were detected after feeding CTB-FIX-lyophilized plant cells for >300 days. Coagulation times were markedly shortened by intravenous FIX in orally tolerized treated dogs, in contrast to control dogs that formed high-titer antibodies to FIX. Commercial-scale production, stability, prolonged storage of lyophilized cells, and efficacy in tolerance induction in a large, non-rodent model of human disease offer a novel concept for oral tolerance and low-cost production and delivery of biopharmaceuticals.
- Subjects :
- 0301 basic medicine
Pharmacology
biology
business.industry
Immunoglobulin E
Immunoglobulin G
3. Good health
Immune tolerance
03 medical and health sciences
Tolerance induction
030104 developmental biology
Immune system
Antigen
Immunology
Drug Discovery
biology.protein
medicine
Genetics
Molecular Medicine
Antibody
business
Molecular Biology
Factor IX
medicine.drug
Subjects
Details
- ISSN :
- 15250016
- Volume :
- 25
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- Molecular Therapy
- Accession number :
- edsair.doi.dedup.....9af9b3c29bd06ce2710db787d05c76fd
- Full Text :
- https://doi.org/10.1016/j.ymthe.2016.11.009